News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arsenal Medical’s Foam Technology for Battlefield Injuries Receives $15.5 Million Phase II Defense Advanced Research Projects Agency Contract


12/10/2012 10:00:46 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--Arsenal Medical, Inc. (Arsenal) today announced that it has been awarded a Phase II contract from the Defense Advanced Research Projects Agency (DARPA) to support continued development of its novel product to control intra-abdominal hemorrhage in soldiers injured on the battlefield. This Phase II award, for $15.5M, has resulted from Arsenal’s successful pre-clinical proof-of-concept work in Phase I of the project and is intended to support both late-stage development and regulatory submission. The Phase II award brings the total amount of money that Arsenal has received from DARPA for this program to $22.5M.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES